Acupoint herbal patching to relieve qi deficiency and constipation during chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers first developed a standardized acupoint application protocol for patients with qi deficiency and constipation using literature review and two rounds of Delphi expert consultation. They will conduct a randomized controlled trial comparing the acupoint application plus routine constipation care versus routine care alone in postoperative colorectal cancer patients receiving chemotherapy. Outcomes include constipation symptom relief, overall clinical efficacy, and patient comfort. The study excludes patients with other organic digestive diseases, severe organ failure, or allergy to the treatment and is conducted at a single center in Hangzhou, Zhejiang.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Clinical diagnosis of colorectal cancer
2. Chemotherapy was performed after surgery
3. Diagnosis of qi deficiency and constipation
4. Age ≥18 years old

Exclusion Criteria:

1. Clinical diagnosis of other digestive tract or anal organic diseases
2. Observed with severe cardiac, hepatic, renal insufficiency or other complications
3. Allergic constitution or allergy to a drug in constipation paste

Where it's running

• The Second Affiliated Hospital of Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Yan Yang
• Email: 2201031@zju.edu.cn
• Phone: 0571-86993370

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gait Changes in Breast Cancer Patients Receiving Chemotherapy

  This study tests how chemotherapy affects walking and balance in women with breast cancer.

  Recruiting Cairo University · Cairo, Cairo Governorate · NCT07894133

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• VR-guided mindfulness for anxiety, sleep, comfort, and fatigue in women with breast cancer undergoing chemotherapy

  This study tests whether a virtual reality–based mindfulness program can help women with breast cancer feel less anxious, sleep better, feel more comfortable, and have less fatigue during chemotherapy.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07731477

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.